A Prospective, Randomized, Controlled, Study Evaluating the Safety and Effectiveness of EVARREST Sealant Matrix in Controlling Mild or Moderate Hepatic Parenchyma or Soft Tissue Bleeding During Open Abdominal, Retroperitoneal, Pelvic and Thoracic (non-cardiac) Surgery in Paediatric Patients
Phase of Trial: Phase IV
Latest Information Update: 15 Dec 2017
At a glance
- Drugs Fibrin (Primary) ; Oxidised cellulose
- Indications Surgical blood loss
- Focus Therapeutic Use
- Sponsors Ethicon
- 12 Dec 2017 Planned End Date changed from 1 Jan 2019 to 1 Jan 2020.
- 12 Dec 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 20 Dec 2016 Planned number of patients changed from 52 to 40.